Timothy C. Greiner MD

Dr. Timothy Greiner has served as the Medical Director of the TNMC Immunohistochemistry Lab and the Molecular Diagnostics Lab during his tenure at UNMC. In both clinical laboratories he has introduced new automated technology, which has helped transform the way clinical testing is performed and has provided research assays for hematopathology colleagues in the Center for Leukemia and Lymphoma Research.

Dr. Greiner’s research interests have included the study of the mutational spectra of genes (ATM, BCL6 and TP53) to help understand the etiology and progression of lymphomas including: diffuse large B-cell lymphoma, mantle cell lymphoma and post-transplant lymphoproliferative disorders (PTLD). His search for a useful molecular biomarker for PTLD has involved the molecular epidemiology of EBV, somatic mutations, single nucleotide polymorphisms and early efforts in characterizing the T-cell repertoire with next generation sequencing.

Currently, he is the Director of Hematopathology in the department . Dr. Greiner's clinical responsibilities include the interpretation of hematopathology-related surgical specimens, bone marrow biopsies, immunohistochemistry, molecular assays including gene rearrangement studies and 50 gene mutation for targeted therapy.

He has developed high performance molecular assays for T-cell receptor gamma rearrangements for diagnosing lymphoma using denaturing gradient gel electrophoresis and capillary electrophoresis. He obtained funds from the University of Nebraska Medical Center/Nebraska Medicine to grow offerings in Clinical oncogenomics in the department . This has resulted in the acquisition of next generation sequencers in the clinical laboratory, the addition of a Bioinformaticist, to enable the development of more multigene panels.